Drug intelligence / Profile preview

GO-M400

Development stage: Preclinical
Lead developer: GO Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GO-M400 is an investigational monoclonal antibody developed by GO Therapeutics in partnership with Astellas. It targets tumor-associated truncated O-glycans, specifically the Tn (GalNAc-alpha-Ser/Thr) and STn (Sialyl-Tn) antigens, which are expressed on the surface of various solid tumor cells as a result of aberrant glycosylation. These antigens are considered highly specific tumor markers as they are absent or minimally expressed in normal tissues. GO-M400 is designed to selectively bind to these 'super-clean' antigens to treat multiple solid tumors while reducing potential toxicity to healthy cells.

Targets

Tn (Tn antigen)STn-MUC1 (Sialyl-Tn-MUC1)

Beyond the preview

Go deeper on GO-M400.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GO-M400.

Explore the full profile